Market Research Logo

Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Regeneron Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Regeneron Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Regeneron Pharmaceuticals, Inc.
  • The report provides overview of Regeneron Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Regeneron Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Regeneron Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Regeneron Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Regeneron Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Regeneron Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Regeneron Pharmaceuticals, Inc. Snapshot
Regeneron Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Regeneron Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Regeneron Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Regeneron Pharmaceuticals, Inc. - Pipeline Products Glance
Regeneron Pharmaceuticals, Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Regeneron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Regeneron Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Regeneron Pharmaceuticals, Inc. - Drug Profiles
aflibercept
Product Description
Mechanism of Action
R&D Progress
alirocumab
Product Description
Mechanism of Action
R&D Progress
sarilumab
Product Description
Mechanism of Action
R&D Progress
dupilumab
Product Description
Mechanism of Action
R&D Progress
suptavumab
Product Description
Mechanism of Action
R&D Progress
fasinumab
Product Description
Mechanism of Action
R&D Progress
(aflibercept + nesvacumab)
Product Description
Mechanism of Action
R&D Progress
(aflibercept + rinucumab)
Product Description
Mechanism of Action
R&D Progress
evinacumab
Product Description
Mechanism of Action
R&D Progress
trevogrumab
Product Description
Mechanism of Action
R&D Progress
ziv-aflibercept (recombinant)
Product Description
Mechanism of Action
R&D Progress
REGN-19081909
Product Description
Mechanism of Action
R&D Progress
REGN-1979
Product Description
Mechanism of Action
R&D Progress
REGN-2810
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Ebola Virus Infection
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Middle East Respiratory Syndrome
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Agonize GITR for Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit LAG-3 for Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit PD-L1 for Oncology
Product Description
Mechanism of Action
R&D Progress
Oligonucleotides to Inhibit Transthyretin for Amyloidosis
Product Description
Mechanism of Action
R&D Progress
REGN-1001
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Blood Cancer and Solid Tumor
Product Description
Mechanism of Action
R&D Progress
Regeneron Pharmaceuticals, Inc. - Pipeline Analysis
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Target
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates
Regeneron Pharmaceuticals, Inc. - Dormant Projects
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
crotedumab
dapiclermin
enoticumab
nesvacumab
REGN-1400
REGN-846
rilonacept
ziv-aflibercept (recombinant)
Regeneron Pharmaceuticals, Inc. - Company Statement
Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Regeneron Pharmaceuticals, Inc., Key Information
Regeneron Pharmaceuticals, Inc., Key Facts
Regeneron Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Regeneron Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2016
Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
Regeneron Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Regeneron Pharmaceuticals, Inc. - Pre-Registration, 2016
Regeneron Pharmaceuticals, Inc. - Phase III, 2016
Regeneron Pharmaceuticals, Inc. - Phase II, 2016
Regeneron Pharmaceuticals, Inc. - Phase I, 2016
Regeneron Pharmaceuticals, Inc. - Preclinical, 2016
Regeneron Pharmaceuticals, Inc. - Discovery, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Target, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Regeneron Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
Regeneron Pharmaceuticals, Inc., Other Locations
Regeneron Pharmaceuticals, Inc., Subsidiaries
Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities
List of Figures
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2016
Regeneron Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report